Evidence map›Paper›PMID 32603630›Full record

ReviewAnnual review of virology2020

Viperin Reveals Its True Function.

Efraín E Rivera-Serrano, Anthony S Gizzi, Jamie J Arnold, Tyler L Grove, Steven C Almo, Craig E Cameron

Open access · greenAbstract readReview
In one paragraph

Review in Annual review of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 163 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Microbial Biotechnology in Medicine.Progress in molecular and subcellular biology · 2026
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Efraín E Rivera-SerranoDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA; email: craig.cameron@med.unc.edu.
Anthony S GizziDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, USA; email: tyler.grove@einsteinmed.org, steve.almo@einsteinmed.org.
Jamie J ArnoldDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA; email: craig.cameron@med.unc.edu.
Tyler L GroveDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, USA; email: tyler.grove@einsteinmed.org, steve.almo@einsteinmed.org.
Steven C AlmoDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, USA; email: tyler.grove@einsteinmed.org, steve.almo@einsteinmed.org.
Craig E CameronDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA; email: craig.cameron@med.unc.edu.
Albert Einstein College of Medicine · USUniversity of North Carolina at Chapel Hill · US

Funding

Protein/Structure CoreP01GM118303 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI GERLT, JOHN A · 2016 to 2020
$11.4M
RNA DEPENDENT RNA POLYMERASE MECHANISMR01AI045818 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARNOLD, JAMIE JON, CAMERON, CRAIG E. · 1999 to 2025
$7.5M
Picornavirus Genome ReplicationR37AI053531 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CRAIG E. CAMERON · 2018 to 2026
$4.8M
NIAID NIH HHS R01 AI045818NIAID NIH HHS R37 AI053531NIGMS NIH HHS P01 GM118303
6 · The paper itself

Abstract

Most cells respond to viral infections by activating innate immune pathways that lead to the induction of antiviral restriction factors. One such factor, viperin, was discovered almost two decades ago based on its induction during viral infection. Since then, viperin has been shown to possess activity against numerous viruses via multiple proposed mechanisms. Most recently, however, viperin was demonstrated to catalyze the conversion of cytidine triphosphate (CTP) to 3'-deoxy-3',4'-didehydro-CTP (ddhCTP), a previously unknown ribonucleotide. Incorporation of ddhCTP causes premature termination of RNA synthesis by the RNA-dependent RNA polymerase of some viruses. To date, production of ddhCTP by viperin represents the only activity of viperin that links its enzymatic activity directly to an antiviral mechanism in human cells. This review examines the multiple antiviral mechanisms and biological functions attributed to viperin.

Indexed as

Cytidine TriphosphateHumansOxidoreductases Acting on CH-CH Group DonorsProteinsRNA-Dependent RNA PolymeraseViperin ProteinVirus Diseases3'-deoxy-3',4'-didehydro-CTPCytidine TriphosphateOxidoreductases Acting on CH-CH Group DonorsProteinsRNA-Dependent RNA PolymeraseRSAD2 protein, humanViperin Proteinchain terminatorinterferonradical SAM proteinRNA-dependent RNA polymeraseRSAD2viperin

Identifiers

PMID32603630
PMCPMC8191541
OpenAlexW3039541860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.